Biotech Stocks: A Bumpy Ride to Recovery
Biotech stocks have had a rough time since their peak in early 2021. They didn't join the market's rebound in 2022, but this summer brought a change. These stocks are tricky because most of them are in the early stages of development. They often don't have earnings or steady revenue, relying instead